TITLE

Hormesis Pervasiveness and its Potential Implications for Pharmaceutical Research and Development

AUTHOR(S)
Maynard, Kenneth I.
PUB. DATE
July 2011
SOURCE
Dose-Response;2011, Vol. 9 Issue 3, p377
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
This mini-review illustrates that hormesis is not only confined to the areas of biochemistry, radiation biology and toxicology, where it is traditionally known, but illustrates, by citing published scientific literature, that it is found across a wide range of biomedical science and clinical medicine such as neuroscience, cardiology and oncology. The use of techniques and technology, including high through-put screening, micro-dosing or phase 0 studies, pharmacometrics and adaptive trial design in the clinic, are proposed to illustrate how acknowledging the potential impact of hormesis throughout different stages of drug discovery and development, including hurdles related to efficacy and safety, could help the pharmaceutical industry address some of its major and frequently mentioned challenges.
ACCESSION #
67699249

 

Related Articles

  • The Paradox of Scientific Excellence and the Search for Productivity in Pharmaceutical Research and Development. Grasela, T H; Slusser, R // Clinical Pharmacology & Therapeutics;May2014, Vol. 95 Issue 5, p521 

    Scientific advances in specialty areas are proceeding at a rapid rate, but the research and development enterprise seems unable to take full advantage. Harnessing the steady stream of knowledge and inventions from different disciplines is the critical management issue of our time. This article...

  • DSIN, Ranbaxy & RSC meet on "Overcoming the Bottlenecks in Drug Discovery and Development".  // Chemical Business;Apr2014, Vol. 28 Issue 4, p57 

    The article discusses the highlights of the symposium "Overcoming the Bottlenecks in Drug Discovery and Development" held in Gurgaon, India on March 20 & 21, 2014. Lectures from leading researchers centered on four key pharmaceutical research and development (R&D) themes, such as biological hit...

  • COMPANY SPOTLIGHT -- Teva Pharmaceutical Industries.  // PharmaWatch: Cancer;Aug2009, Vol. 8 Issue 8, p20 

    The article profiles Israel-based generic pharmaceutical drugs manufacturer Teva Pharmaceutical Industries Ltd. The company has been operating in pharmaceuticals and active pharmaceutical ingredients (APIs). Teva has established research and development (R&D) units in which one focuses on the...

  • How Informatics Unites Teams. Minkel, J.R. // Drug Discovery & Development;Jan2005, Vol. 8 Issue 1, p26 

    Examines the role of informatics in drug development. Profile on Johnson & Johnson Pharmaceutical Research and Development Program and its management of four research sites. Creation of a leap frog project management tool designed to prevent researchers from duplicating their research work;...

  • KEY FACTORS IN THE RISING COST OF NEW DRUG DISCOVERY AND DEVELOPMENT. Dickson, Michael; Gagnon, Jean Paul // Nature Reviews Drug Discovery;May2004, Vol. 3 Issue 5, p417 

    Describes how the environment for pharmaceutical research and development (R&D) has changed over time and the effect of the changes on R&D cost, risk and time invested. Literature on the cost of drug discovery and development for new chemical entity; Efforts of the pharmaceutical industry to...

  • MAKING KNOWLEDGE AND MAKING DRUGS? EXPERIMENTING WITH UNIVERSITY INNOVATION CAPACITY. Vertinsky, Liza // Emory Law Journal;2013, Vol. 62 Issue 4, p741 

    No abstract available.

  • J&J Expands R&D in India.  // Chemical Week;5/23/2007, Vol. 169 Issue 18, p25 

    The article reports on the expansion of the analytical and pharmaceutical development center (APDC) of Johnson & Johnson Pharmaceutical Research & Development and Janssen-Cilag at Mumbai, India and are building a pharma research facility at the same site. The APDC will be a hub for analytical...

  • Stephen Ubl, President and CEO. Ubl, Stephen // Chain Drug Review;1/4/2016, Vol. 38 Issue 1, p135 

    The author offers his perspectives on the outlook of the pharmacy industry for 2016. Topics discussed include the increase in drug development and medicines that have the potential to be first-in-class therapies, advancements in research and development (R&D) for cancer, high cholesterol and...

  • A decade of innovation in pharmaceutical R&D: the Chorus model. Owens, Paul K.; Raddad, Eyas; Miller, Jeffrey W.; Stille, John R.; Olovich, Kenneth G.; Smith, Neil V.; Jones, Rosie S.; Scherer, Joel C. // Nature Reviews Drug Discovery;Jan2015, Vol. 14 Issue 1, p17 

    Chorus is a small, operationally independent clinical development organization within Eli Lilly and Company that specializes in drug development from candidate selection to clinical proof of concept. The mission of Chorus is to achieve proof of concept rapidly and at a low cost while positioning...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics